Lv3
247 积分 2021-05-10 加入
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
19天前
已完结
Topoisomerase I inhibitors: camptothecins and beyond
1个月前
已完结
Stability Studies of Binding and Functional Anti-Vaccine Antibodies
2个月前
已完结
“Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics
4个月前
已完结
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
4个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
5个月前
已完结
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial
6个月前
已完结
Soluble levels of 4‐1BB (CD137) and OX40 (CD134) are associated with cancer progression in gastric adenocarcinoma
7个月前
已完结
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
8个月前
已完结
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
8个月前
已完结
皖公网安备34019202002308
